SAFETY DATA SHEET



Hardtop XP Alu Comp A

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Product name : Hardtop XP Alu Comp A UFI : P6HJ-T1A1-400E-3SHU

Product code : 17520
Product description : Paint.
Product type : Liquid.
Other means of : Not available.

identification

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use in coatings - Industrial use
Use in coatings - Professional use

1.3 Details of the supplier of the safety data sheet

Jotun A/S P.O.Box 2021 3202 Sandefjord Norway

Tel: + 47 33 45 70 00 Fax: +47 33 45 72 42 E-mail: SDSJotun@jotun.no

National contact

Jotun Paints Europe (Ltd). Unit K7, Marina Commercial Park Centre Park Road Cork Ireland

Tel: +353 214 965955 Fax: +353 214 965992

SDSJotun@jotun.com

1.4 Emergency telephone number

Poisons Information Centre of Ireland: +353 1 809 3000 (8am-10pm, 7 days a week)

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition: Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Flam. Liq. 3, H226 Skin Sens. 1, H317 Aquatic Chronic 3, H412

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

Date of issue/Date of revision : 27.03.2023 Date of previous issue : No previous validation Version : 1 1/19

SECTION 2: Hazards identification

2.2 Label elements

Hazard pictograms





Signal word : Warning.

Hazard statements : H226 - Flammable liquid and vapour.

H317 - May cause an allergic skin reaction.

H412 - Harmful to aquatic life with long lasting effects.

Precautionary statements

General : Not applicable.

Prevention : P280 - Wear protective gloves.

P210 - Keep away from heat, hot surfaces, sparks, open flames and other ignition

sources. No smoking.

P273 - Avoid release to the environment.

P261 - Avoid breathing vapour.

Response : P362 + P364 - Take off contaminated clothing and wash it before reuse.

P302 + P352 - IF ON SKIN: Wash with plenty of water.

P333 + P313 - If skin irritation or rash occurs: Get medical advice or attention.

Storage : Not applicable.

: P501 - Dispose of contents and container in accordance with all local, regional, **Disposal**

national and international regulations.

Hazardous ingredients : n-butvl methacrvlate

decanedioic acid, 1,10-bis(1,2,2,6,6-pentamethyl-4-piperidinyl) ester, mixt. with

1-methyl 10-(1,2,2,6,6-pentamethyl-4-piperidinyl) decanedioate

2-Hydroxyethyl methacrylate

Supplemental label

elements

articles

: Not applicable.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and

: Not applicable.

Special packaging requirements

Containers to be fitted

with child-resistant

fastenings

: Not applicable.

Tactile warning of danger : Not applicable.

2.3 Other hazards

Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII

: This mixture does not contain any substances that are assessed to be a PBT or a

Other hazards which do not result in classification : None known.

Date of issue/Date of revision : 27.03.2023 Date of previous issue Version:1 2/19 : No previous validation

SECTION 3: Composition/information on ingredients

3.2 Mixtures : Mixture

| Product/ingredient name | Identifiers | % | Classification | Specific Conc. Limits, M-factors and ATEs | Туре |
|---|--|-----------|---|---|---------|
| n-butyl acetate | REACH #: 01-2119485493-29 EC: 204-658-1 CAS: 123-86-4 | ≥10 - ≤17 | Flam. Liq. 3, H226 STOT SE 3, H336 EUH066 | - | [1] [2] |
| xylene | REACH #: 01-2119488216-32 EC: 215-535-7 CAS: 1330-20-7 Index: 601-022-00-9 | <10 | Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 Asp. Tox. 1, H304 Aquatic Chronic 3, H412 | ATE [Dermal] = 1100 mg/kg ATE [Inhalation (vapours)] = 20 mg/ I | [1] [2] |
| ethylbenzene | REACH #: 01-2119489370-35 EC: 202-849-4 CAS: 100-41-4 Index: 601-023-00-4 | ≤3 | Flam. Liq. 2, H225 Acute Tox. 4, H332 STOT RE 2, H373 (hearing organs) Asp. Tox. 1, H304 Aquatic Chronic 3, H412 | ATE [Inhalation (vapours)] = 17.8 mg/l | [1] [2] |
| hydrocarbons, C9, aromatics | REACH #: 01-2119455851-35 EC: 265-199-0 CAS: 128601-23-0 | ≤2.7 | Flam. Liq. 3, H226 STOT SE 3, H335 STOT SE 3, H336 Asp. Tox. 1, H304 Aquatic Chronic 2, H411 | - | [1] |
| hydrocarbons, C10-C13, n-alkanes, isoalkanes, cyclics, < 2% aromatics | REACH #: 01-2119457273-39 EC: 265-150-3 CAS: - | ≤3 | Asp. Tox. 1, H304 EUH066 | - | [1] [2] |
| Hexanoic acid, 2-ethyl-, zinc salt, basic | REACH #: 01-2119979093-30 EC: 286-272-3 CAS: 85203-81-2 | ≤0.3 | Eye Irrit. 2, H319 Repr. 2, H361d Aquatic Chronic 3, H412 | - | [1] |
| n-butyl methacrylate | REACH #: 01-2119486394-28 EC: 202-615-1 CAS: 97-88-1 Index: 607-033-00-5 | ≤0.3 | Flam. Liq. 3, H226 Skin Irrit. 2, H315 Eye Irrit. 2, H319 Skin Sens. 1, H317 STOT SE 3, H335 | - | [1] |
| decanedioic acid, 1,10-bis (1,2,2,6,6-pentamethyl-4-piperidinyl) ester, mixt. with 1-methyl 10-(1,2,2,6,6-pentamethyl-4-piperidinyl) decanedioate | CAS: 1065336-91-5 | ≤0.3 | Skin Sens. 1A, H317 Repr. 2, H361f Aquatic Acute 1, H400 Aquatic Chronic 1, H410 | M [Acute] = 1 M [Chronic] = 1 | [1] |
| 2-Hydroxyethyl methacrylate | EC: 212-782-2 CAS: 868-77-9 Index: 607-124-00-X | ≤0.3 | Skin Irrit. 2, H315 Eye Irrit. 2, H319 Skin Sens. 1, H317 | - | [1] |
| Oleic acid, compound | EC: 251-846-4 | ≤0.1 | Skin Irrit. 2, H315 | M [Acute] = 10 | [1] |

Date of issue/Date of revision: 27.03.2023Date of previous issue: No previous validationVersion: 13/19

| Hardtop XP Alu Com | lardtop XP Alu Comp A | | | | | |
|--------------------|-------------------------|--|--|--|--|--|
| SECTION 3: | Composition/information | on ingredients | | | | |
| | CAS: 34140-91-5 | Eye Irrit. 2, H319 STOT RE 2, H373 Aquatic Acute 1, H400 Aquatic Chronic 2, H411 | | | | |
| | | See Section 16 for the full text of the H statements declared above. | | | | |

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Type

Ingestion

- [1] Substance classified with a health or environmental hazard
- [2] Substance with a workplace exposure limit

Occupational exposure limits, if available, are listed in Section 8.

SECTION 4: First aid measures

4.1 Description of first aid measures

| General | : In all cases of doubt, or when symptoms persist, seek medical attention. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and seek medical advice. |
|-------------|---|
| Eye contact | Remove contact lenses, irrigate copiously with clean, fresh water, holding the eyelids apart for at least 10 minutes and seek immediate medical advice. |
| Inhalation | : Remove to fresh air. Keep person warm and at rest. If not breathing, if breathing is |

: Remove to fresh air. Keep person warm and at rest. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel.

Skin contact : Remove contaminated clothing and shoes. Wash skin thoroughly with soap and water or use recognised skin cleanser. Do NOT use solvents or thinners.

: If swallowed, seek medical advice immediately and show the container or label. Keep person warm and at rest. Do NOT induce vomiting.

Protection of first-aiders : No action shall be taken involving any personal risk or without suitable training. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation.

Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

4.2 Most important symptoms and effects, both acute and delayed

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapour concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Symptoms and signs include headache, dizziness, fatigue, muscular weakness, drowsiness and, in extreme cases, loss of consciousness.

Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption through the skin.

If splashed in the eyes, the liquid may cause irritation and reversible damage.

Ingestion may cause nausea, diarrhea and vomiting.

This takes into account, where known, delayed and immediate effects and also chronic effects of components from short-term and long-term exposure by oral, inhalation and dermal routes of exposure and eye contact.

Contains n-butyl methacrylate, decanedioic acid, 1,10-bis(1,2,2,6,6-pentamethyl-4-piperidinyl) ester, mixt. with 1-methyl 10-(1,2,2,6,6-pentamethyl-4-piperidinyl) decanedioate, 2-hydroxyethyl methacrylate. May produce an allergic reaction.

Over-exposure signs/symptoms

Date of issue/Date of revision : 27.03.2023 Date of previous issue : No previous validation Version : 1 4/19

SECTION 4: First aid measures

Eye contact : No specific data. Inhalation : No specific data.

Skin contact : Adverse symptoms may include the following:

irritation redness

Ingestion : No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician : Treat symptomatically. Contact poison treatment specialist immediately if large

quantities have been ingested or inhaled.

Specific treatments : No specific treatment.

See toxicological information (Section 11)

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media

: Recommended: alcohol-resistant foam, CO₂, powders, water spray.

Unsuitable extinguishing

: Do not use water jet.

media

5.2 Special hazards arising from the substance or mixture

Hazards from the substance or mixture : Fire will produce dense black smoke. Exposure to decomposition products may cause a health hazard.

Hazardous combustion products

: Decomposition products may include the following materials: carbon monoxide, carbon dioxide, smoke, oxides of nitrogen.

5.3 Advice for firefighters

Special protective actions for fire-fighters

: Cool closed containers exposed to fire with water. Do not release runoff from fire to drains or watercourses.

Special protective equipment for fire-fighters : Appropriate breathing apparatus may be required.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel

: Exclude sources of ignition and ventilate the area. Avoid breathing vapour or mist. Refer to protective measures listed in sections 7 and 8.

For emergency responders

: If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

6.2 Environmental precautions

: Do not allow to enter drains or watercourses. If the product contaminates lakes, rivers, or sewers, inform the appropriate authorities in accordance with local regulations.

6.3 Methods and material for containment and cleaning up

: Contain and collect spillage with non-combustible, absorbent material e.g. sand. earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations (see Section 13). Preferably clean with a detergent. Avoid using solvents.

Date of issue/Date of revision : 27.03.2023 Version : 1 5/19 Date of previous issue : No previous validation

SECTION 6: Accidental release measures

6.4 Reference to other sections

: See Section 1 for emergency contact information.

See Section 8 for information on appropriate personal protective equipment.

See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

Prevent the creation of flammable or explosive concentrations of vapours in air and avoid vapour concentrations higher than the occupational exposure limits.

In addition, the product should only be used in areas from which all naked lights and other sources of ignition have been excluded. Electrical equipment should be protected to the appropriate standard.

Mixture may charge electrostatically: always use earthing leads when transferring from one container to another.

Operators should wear antistatic footwear and clothing and floors should be of the conducting type.

Keep away from heat, sparks and flame. No sparking tools should be used.

Avoid contact with skin and eyes. Avoid the inhalation of dust, particulates, spray or mist arising from the application of this mixture. Avoid inhalation of dust from sanding.

Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed.

Put on appropriate personal protective equipment (see Section 8).

Never use pressure to empty. Container is not a pressure vessel.

Always keep in containers made from the same material as the original one.

Comply with the health and safety at work laws.

Do not allow to enter drains or watercourses.

Information on fire and explosion protection

Vapours are heavier than air and may spread along floors. Vapours may form explosive mixtures with air.

When operators, whether spraying or not, have to work inside the spray booth, ventilation is unlikely to be sufficient to control particulates and solvent vapour in all cases. In such circumstances they should wear a compressed air-fed respirator during the spraying process and until such time as the particulates and solvent vapour concentration has fallen below the exposure limits.

7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations.

Notes on joint storage

Keep away from: oxidising agents, strong alkalis, strong acids.

Additional information on storage conditions

Observe label precautions. Store in a dry, cool and well-ventilated area. Keep away from heat and direct sunlight. Keep away from sources of ignition. No smoking. Prevent unauthorised access. Containers that have been opened must be carefully resealed and kept upright to prevent leakage.

Seveso Directive - Reporting thresholds

Danger criteria

| Category | Notification and MAPP threshold | Safety report threshold |
|----------|---------------------------------|-------------------------|
| P5c | 5000 tonne | 50000 tonne |

See Technical Data Sheet / packaging for further information.

7.3 Specific end use(s)

Recommendations : Not available.

Industrial sector specific : Not available.

solutions

Date of issue/Date of revision: 27.03.2023Date of previous issue: No previous validationVersion: 1

SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

8.1 Control parameters

Occupational exposure limits

| Product/ingredient name | Exposure limit values |
|---|--|
| n-butyl acetate | EH40/2005 WELs (United Kingdom (UK), 1/2020). |
| | STEL: 966 mg/m³ 15 minutes. |
| | STEL: 200 ppm 15 minutes. |
| | TWA: 724 mg/m³ 8 hours. |
| | TWA: 150 ppm 8 hours. |
| xylene | EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed |
| | through skin. |
| | STEL: 441 mg/m³ 15 minutes. |
| | STEL: 100 ppm 15 minutes. |
| | TWA: 220 mg/m³ 8 hours. |
| | TWA: 50 ppm 8 hours. |
| ethylbenzene | EH40/2005 WELs (United Kingdom (UK), 1/2020). Absorbed |
| | through skin. |
| | STEL: 552 mg/m³ 15 minutes. |
| | STEL: 125 ppm 15 minutes. |
| | TWA: 100 ppm 8 hours. |
| | TWA: 441 mg/m³ 8 hours. |
| hydrocarbons, C10-C13, n-alkanes, isoalkanes, | EH40/2005 WELs (United Kingdom (UK), 1/2005). |
| cyclics, < 2% aromatics | STEL: 850 mg/m³ 15 minutes. Form: All forms |
| | STEL: 150 ppm 15 minutes. Form: All forms |
| | TWA: 566 mg/m ³ 8 hours. Form: All forms |
| | TWA: 100 ppm 8 hours. Form: All forms |

Recommended monitoring procedures

: Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

DNELs/DMELs

| Product/ingredient name | Type | Exposure | Value | Population | Effects |
|-------------------------|------|--------------------------|-----------------------|--------------------------------------|----------|
| n-butyl acetate | DNEL | Short term Inhalation | 960 mg/m ³ | Workers | Systemic |
| | DNEL | Short term Inhalation | 960 mg/m ³ | Workers | Local |
| | DNEL | Long term Inhalation | 480 mg/m ³ | Workers | Systemic |
| | DNEL | Long term Inhalation | 480 mg/m ³ | Workers | Local |
| | DNEL | Short term Inhalation | 859.7 mg/ m³ | General population [Consumers] | Systemic |
| | DNEL | Short term Inhalation | 859.7 mg/ m³ | General population [Consumers] | Local |
| | DNEL | Long term Inhalation | 102.34 mg/ m³ | | Systemic |
| | DNEL | Long term | 102.34 mg/ | | Local |

Date of issue/Date of revision : 27.03.2023 Date of previous issue : No previous validation Version : 1 7/19

SECTION 8: Exposure controls/personal protection

| Inhalation DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | | | | | | |
|--|---|-----------------|---------------|-------------------|------------------------|--------------|-------------|
| DNEL Short term Oral DNEL Long term Oral DNEL Short term Dermal DNEL Short term Dermal DNEL Short term Dermal DNEL Short term Inhalation DNEL Short term Inh | | | | Inhalation | m³ | population | |
| DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term DNEL DNE DNEL Long term DNEL DNE DNEL DNE DNET DNEL DNE DNE DNEL DNE DNET DNE DNET DNE DNET DNE DNET DNE DNET DNE DNET DNE | | | | | - " | | |
| DNEL Long term Oral bridged by the proposal properties of the prop | | | DNEL | Short term Oral | | | Systemic |
| DNEL Short term Dermal DNEL Cong term Inhalation DNEL Cong term Inhala | | | | | | | |
| DNEL Short term Dermal DNEL Long term Inhalation DNEL Long term Inhala | | | DNEL | Long term Oral | | _ | Systemic |
| DNEL Short term Dermal DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Inhal | | | | | bw/day | population | |
| DNEL Long term inhalation DNEL Long term Inh | | | DNEL | Short term Dermal | 6 mg/kg | General | Systemic |
| DNEL Long term inhalation DNEL Long term Inh | | | | | bw/day | population | |
| DNEL | | | DNEL | Short term Dermal | | | Systemic |
| DNEL Long term inhalation DNEL Short term Inhalation DNEL Long term DNEL Long term DNEL Long term Inhalation DNEL Long term DNEL Long term DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term DNEL Long term DNEL Short term Inhalation DNEL Long term DNEL Long term DNEL Short term Inhalation DNEL Long term DNEL Short term Inhalation DNEL Long term DNEL | | | | | | | , |
| DNEL Short term Inhalation DNEL Cocal Inhalation DNEL Conservation DNEL Conservation Inhalation DNEL Conservation DNEL Conserva | | | DNEL | Long term | | General | Local |
| DNEL Short term Short ter | | | | | g | | |
| Inhalation DNEL Short term Inhalation DNEL Short term Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL DNEL Short term Inhalation DNEL DNEL DNET DNEL DNET DNEL DNEL DNET DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | | DNEI | | 300 ma/m ³ | | Local |
| DNEL DNEL Long term 10 mail DNEL Long term 12 mg/m² DNEL Long term DNEL Short term DNEL Short term DNEL Short term DNEL Long term DNEL DNEM | | | DIVLL | | 300 mg/m | | Local |
| Inhalation DNEL DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation | | | DNEI | | 300 ma/m ³ | | Systemic |
| DNEL Dong term Inhalation DNEL Long term Dermal Inhalation DNEL Long term More Inhalation DNEL Long term Dormal DNEL Long term More Inhalation DNEL Dormal DNEL DORMA DNEL DNEL DNE | | | DINEL | | 300 mg/m | | Systernic |
| Inhalation DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | | DNE | | 000/3 | | 1 1 |
| DNEL Short term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Habalation DNEL Short term Habalation DNEL Long term Dermal DNEL Long term Habalation DNEL Long term Dermal DNEL Long term Habalation DNEL H | | | DNEL | | 300 mg/m ³ | vvorkers | Local |
| Inhalation DNEL Sort term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term 12 mg/m² population DNEL Long term 12 mg/m² population DNEL Long term 15 mg/m² population DNEL Long term 16-5.3 mg/m² population DNEL Sort term 16-5.3 mg/m² population DNEL Long term 260 mg/m² population DNEL Sort term 260 mg/m² population DNEL Long term 27 mg/m² population DNEL Long term 12.5 mg/m² population DNEL Long term 21 mg/m² population DNEL Long term 21 population DNEL Long term 31 population DNEL population DNEL population 32 | | | DAIEI | | 000 / 3 | \A/ I | |
| DNEL Long term Dermal DNEL Dong term Dong Dopulation DNEL Short term Dong Dopulation DNEL Dong term Dnemal DNEL Dnemal Dnema | | | DNFL | | งบบ mg/m³ | vvorkers | Local |
| Inhalation DNEL DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Dong term Inhalation DNEL Dong term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Dong term Inhalation DNEL DNEL Dong term Inhalation DNEL Dong term Dermal DNEL Dong term Dermal DNEL Dong term Inhalation DNEL Don | | | - · · - · | | | | |
| DNEL Long term Dermal Dwiday Dwiday Toropical DNEL Long term Dermal Inhalation DNEL Short term Inhalation DNEL Long term Oral DNEL Long term Oral DNEL Long term Inhalation DNEL Long term Inhalation DNEL Dong term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Cong term Inhalation DNEL Short term Inhalation DNEL Cong term Inhalation DNEL Dong term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term DNEL Long term Dermal DNEL Long term DNEL Long term DNEL Long term DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Dradinalation DNEL Long term Dradinalation DNEL Long term Dradinalation DNEL DNEL Long term Dradinalation DNEL Short term Inhalation DNED DNED DNED DNED DNED DNED DNED DNE | | | DNEL | | 600 mg/m ³ | Workers | Systemic |
| DNEL Long term Dermal Dwilday 7 mg/kg bw/day 12 mg/m³ population Workers Systemic DNEL Long term 1 halation DNEL Long term 1 halation DNEL Long term 1 halation DNEL Short term 1 halation DNEL Long term Dermal DNEL Long term DNEL Long term Dermal DNEL Long term Dermal DNEL Long term DNEL DNEL DNET DNEL Long term DNEL DNEL DNET DNEL DNEL DNET DNEL DNEL DNEL DNET DNEL DNEL DNET DNEL DNEL DNET DNEL DNEL DNEL DNET DNEL DNEL DNEL DNET DNEL DNEL DNET DNEL DNET DNEL DNET DNEL DNET DNEL DNEL DNET DNEM DNEL DNEL DNET DNET DNEM DNEL DNET DNEM DNEL DNET DNEM DNED DNEL DNET DNEM DNED DNEL DNET DNEM DNED DNEL DNET DNEM DNED DNED DNEL DNET DNEM DNED DNED DNED DNED DNED DNED DNED | | | | | | _ | |
| DNEL Long term Dermal 12 mg/kg bw/day 12 mg/m³ linhalation DNEL Long term 12 mg/m³ linhalation Morkers Systemic DNEL Long term 12 mg/m³ linhalation Morkers Systemic DNEL Long term 1260 mg/m³ linhalation DNEL Short term 1260 mg/m³ linhalation DNEL Long term 125 mg/kg bw/day DNEL Long term Dermal DNEL Long term DNEL DNEL Long term DNEL DNEL Long term DNEL DNEL DNEL DNEL DNEL DNEL DNET DNEL DNEL DNET DNEL DNEL DNET DNED DW/day DNEL DNET DNEL DNET DNED DW/day DNEL DNET DNEL DNET DNED DW/day DNED | | | DNEL | Long term Dermal | | | Systemic |
| DNEL Long term Inhalation DNEL Long term General population Workers Systemic Inhalation DNEL Long term General population Workers Systemic Inhalation DNEL Short term General population Workers Local Inhalation DNEL Long term Common General population Workers General Systemic population General Systemic Inhalation DNEL Short term General General Systemic General Systemic DNEL Long term Gral 1.6 mg/kg bw/day 15 mg/m³ Inhalation DNEL Long term Gral 1.6 mg/kg bw/day DNEL Long term Torm General Systemic DNEL Cong term Torm Gene | | | | | | | |
| DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | | DNEL | Long term Dermal | | Workers | Systemic |
| xylene DNEL Inhalation Long term Long term Systemic Local population Complete Comp | | | | | | | |
| xylene DNEL Long term Lon | | | DNEL | Long term | 12 mg/m³ | General | Systemic |
| xylene DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Dermal Inhalation DNEL Short term Inhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal Inhalation DNEL Short term Inhalation DNEL Long term Dermal Inhalation DNEL Short term Inhalation DNEL Long term Dermal Inhalation DNEL Short term Inhalation DNEL Long term Dermal Inhalation DNEL Short term Inhalation DNEL Long term Dermal Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Dermal Inhalation DNEL Short term In | | | | | | | |
| xylene DNEL Long term Inhalation DNEL Short term 260 mg/m³ General population Systemic population Workers DNEL Long term 12.5 mg/kg bw/day 65.3 mg/m³ Inhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal DNEL Short term Unhalation DNEL DNEL Short term DNEL Long term Dermal DNEL Long term Dopulation DNEL Long term Dermal DNEL Long term Dnemal Dnem | | | DNEL | | 48 mg/m³ | Workers | Systemic |
| Inhalation DNEL Short term 1 | | | | Inhalation | | | |
| DNEL Short term Inhalation DNEL Long term Oral Long term Oral Long term Oral Long term Oral Inhalation DNEL Long term Oral Long term Oral Inhalation Oral Inha | | xylene | DNEL | | 65.3 mg/m ³ | General | Local |
| Inhalation Short term Inhalation DNEL Ong term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term DNEL Long term DNEL Long term Inhalation DNEL Short term Inhalation DNEL DNEL Short term Inhalation DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | | | | | | |
| DNEL Short term Inhalation DNEL Long term Inhalation DNEL Long term Oral Long term Oppulation DNEL Long term Oppulation DNEL Long term Oppulation DNEL Long term Oppulation DNEL DNEL Long term Oppulation Oppula | | | DNEL | Short term | 260 mg/m ³ | General | Local |
| Inhalation DNEL Long term (halation) DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Dermal DNEL Long term (halation) DNEL Short term (halation) DNEL Long term Oral DNEL Long term (halation) DNEL DNEL Long term (halation) DNEL DNEL Long term (halation) DNEL Short term (halation) DNEL Shor | | | | Inhalation | | population | |
| DNEL Long term Inhalation Long term Oral DNEL Long term Dermal Inhalation DNEL Long term Dermal DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | | DNEL | Short term | 260 mg/m ³ | General | Systemic |
| Inhalation DNEL DNEL DNEL DNEL Long term Oral DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL DNEL Long term DNEL DNEL Long term DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | | | Inhalation | | population | |
| DNEL Long term Oral DNEL Long term Oral Long term Oral DNEL Long term Dermal Inhalation DNEL Long term Dermal Inhalation DNEL Long term Dermal Inhalation DNEL Short term Inhalation DNEL Long term Oral DNEL Long term Oral Inhalation DNEL Short term Inhalation DNEL Long term Oral Inhalation DNEL Long term Oral Inhalation DNEL Short term Inhalation DNEL Long term Oral Inhalation DNEL Long term Oral Inhalation DNEL Long term Oral Inhalation Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL Long term Dermal Inhalation DNEL Short term Inhala | | | DNEL | Long term | 221 mg/m ³ | Workers | Local |
| DNEL Long term Inhalation DNEL Long term Dermal DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Oral DNEL Long term Oral DNEL Long term Market Short term Inhalation DNEL Short term Inhalation DNEL Long term Oral DNEL Long term Oral DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Toral DNEL Coral | | | | Inhalation | - | | |
| DNEL Long term Inhalation DNEL Long term Dermal DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Oral DNEL Long term Oral DNEL Long term Market Short term Inhalation DNEL Short term Inhalation DNEL Long term Oral DNEL Long term Oral DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Toral DNEL Coral | | | DNEL | Long term Oral | 12.5 mg/ | General | Systemic |
| DNEL Long term Inhalation DNEL Long term Dermal DNEL Short term Inhalation DNEL Long term Oral DNEL Long term Dermal DNEL Long term Oral DNEL Long term Dermal DNEL Short term Dermal Developed | | | | • | | | |
| Inhalation Long term Dermal 125 mg/kg bw/day 212 mg/kg bw/day 212 mg/kg bw/day 221 mg/m³ Workers Systemic | | | DNEL | Long term | | | Systemic |
| DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dnemal DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Inhalation DNEL Long term Oral DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dnemal DNEL Short term Dnemal DNEL Short term Dnemal DNEL Short term Dnemal DNEL Short term Dnemal Dnemal DNEL Short term Dnemal | | | | | 3, | | * |
| DNEL Long term Dermal bw/day population Workers Systemic DNEL Long term 221 mg/m³ Workers Systemic DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term 442 mg/m³ Workers Local DNEL Short term 442 mg/m³ Workers Systemic Inhalation DNEL Long term Oral 1.6 mg/kg bw/day DNEL Long term 15 mg/m³ General population DNEL Long term 15 mg/m³ Systemic DNEL Long term 15 mg/m³ Workers Systemic DNEL Long term 15 mg/m³ Systemic DNEL Long term 180 mg/kg bw/day DNEL Short term 193 mg/m³ Workers Systemic DNEL Short term 193 mg/m³ Workers Systemic | | | DNEL | | 125 ma/ka | | Systemic |
| DNEL Long term Dermal bw/day DNEL Long term 221 mg/kg bw/day DNEL Short term 442 mg/m³ Workers DNEL Short term 442 mg/m³ Workers DNEL Short term 442 mg/m³ Workers Ethylbenzene DNEL Long term Oral 1.6 mg/kg bw/day DNEL Long term 07al 1.5 mg/m³ General population DNEL Long term 15 mg/m³ General population DNEL Long term 15 mg/m³ General population DNEL Long term 15 mg/m³ Workers DNEL Long term 180 mg/kg bw/day DNEL Long term Dermal 180 mg/kg bw/day DNEL Short term 180 mg/kg bw/day DNEL Short term 180 mg/kg bw/day DNEL Short term 293 mg/m³ Workers DNEL Local | | | - · · | | | | , |
| DNEL Long term bw/day 221 mg/m³ Workers Systemic | | | DNFI | Long term Dermal | | | Systemic |
| DNEL Long term Inhalation DNEL Short term 442 mg/m³ Workers Enhylbenzene DNEL Long term 442 mg/m³ Workers DNEL Long term Oral 1.6 mg/kg bw/day DNEL Long term 15 mg/m³ General population DNEL Long term 15 mg/m³ Workers DNEL Long term 77 mg/m³ Workers DNEL Long term 77 mg/m³ Workers DNEL Long term 180 mg/kg bw/day DNEL Long term Dermal 180 mg/kg bw/day DNEL Short term Inhalation DNEL Long term Dermal Systemic DNEL Short term 293 mg/m³ Workers DNEL Short term Inhalation DNEL Long term Dermal Systemic DNEL Short term 293 mg/m³ Workers DNEL Local | | | | | | | , |
| Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Oral DNEL Long term Inhalation DNEL Long term Dermal DNEL Short term Dermal | | | DNFI | Long term | | Workers | Systemic |
| DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Long term Oral DNEL Long term Inhalation DNEL Short term Inhalation | | | | | <u></u> | ., | - , |
| Inhalation Short term Inhalation DNEL DNEL DNEL Long term Oral DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL | | | DNFI | | 442 ma/m³ | Workers | Local |
| ethylbenzene DNEL Short term Inhalation DNEL Long term Oral DNEL Long term 15 mg/m³ General population DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal DNEL Derman Dermal DNEL Derman Dermal DNEL Derman | | | LL | | 9/ | | |
| ethylbenzene DNEL Long term Oral DNEL Long term (1.6 mg/kg) bw/day DNEL Long term (15 mg/m³ General population DNEL Long term (15 mg/m³ General population DNEL Long term (15 mg/m³ Workers Systemic population) DNEL Long term (180 mg/kg) bw/day DNEL Short term (180 mg/kg) bw/day | | | DNEI | | 442 ma/m³ | Workers | Systemic |
| ethylbenzene DNEL Long term Oral DNEL Long term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation | | | ۱۹LL | | 1-12 mg/m | V V OI NOI O | Systemio |
| DNEL Long term 15 mg/m³ General population DNEL Long term 77 mg/m³ Workers Systemic Inhalation DNEL Long term Dermal 180 mg/kg bw/day DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term 293 mg/m³ Workers Local | | ethylbenzene | DNFI | | 1.6 ma/ka | General | Systemic |
| DNEL Long term Inhalation DNEL Long term Composition DNEL Long term Domal Long term Domal Long term Domal DNEL Short term Inhalation DNEL Short term Systemic Systemic Workers DNEL Short term Systemic S | | 53.13.501120110 | ∠. ₹∟∟ | Long tolli Olai | | | - 30.011110 |
| Inhalation DNEL Long term Inhalation DNEL Long term Dermal DNEL Short term Inhalation Inhalation DNEL Short term Inhalation Inhalation DNEL Short term Inhalation Inhalation Inhalation DNEL Short term 293 mg/m³ Workers Local | | | DNEI | I ong term | | | Systemic |
| DNEL Long term 177 mg/m³ Workers Systemic DNEL Long term Dermal 180 mg/kg bw/day DNEL Short term 193 mg/m³ Workers Systemic DNEL Short term 293 mg/m³ Workers Local | | | DIVLL | | 15 mg/m | | Systemio |
| Inhalation Long term Dermal DNEL Short term Inhalation UNEL Short term Inhalation | | | DNEI | | 77 ma/m³ | | Systemic |
| DNEL Long term Dermal 180 mg/kg bw/day DNEL Short term Inhalation 180 mg/kg bw/day 293 mg/m³ Workers Local | | | DINCL | | r r mg/m | 4 4 OI VG12 | Oyaleiiill |
| DNEL Short term 293 mg/m³ Workers Local Inhalation | | | DNEI | | 180 ma/ka | Workers | Systemic |
| DNEL Short term 293 mg/m³ Workers Local Inhalation | | | DINCL | Long term Dermal | | 4 4 OI VG12 | Oyaleiiill |
| Inhalation | | | DNEI | Short term | | Workers | Local |
| | | | DINCL | | 290 mg/m² | 4 4 OI VG1 2 | Local |
| Divice Long term 442 mg/m Workers Local | | | DMEI | | 442 mg/m³ | Workers | Local |
| | ļ | | ıvıLL. | Long tolli | 1-12 mg/m | TYORKOIS | |

Date of issue/Date of revision: 27.03.2023Date of previous issue: No previous validationVersion: 18/19

SECTION 8: Exposure controls/personal protection

| | | • | | | |
|---------------------------------------|----------|---------------------------------|--|------------------------|-----------|
| | 51451 | Inhalation | 004 / 2 | | |
| | DMEL | Short term | 884 mg/m ³ | Workers | Systemic |
| hydroparhana CO aramatica | DNIEL | Inhalation | 10 5 mg/ | Morkoro | Cuatamia |
| hydrocarbons, C9, aromatics | DNEL | Long term Dermal | 12.5 mg/ kg bw/day | Workers | Systemic |
| | DNEL | Long term | 151 mg/m ³ | Workers | Systemic |
| | DIVLL | Inhalation | 1011119/111 | VVOIRCIS | Oysternic |
| | DNEL | Long term Dermal | 7.5 mg/kg | General | Systemic |
| | | | bw/day | population | |
| | | | , and the second | [Consumers] | |
| | DNEL | Long term | 32 mg/m³ | General | Systemic |
| | | Inhalation | | population | |
| | 5.151 | | " | [Consumers] | |
| | DNEL | Long term Oral | 7.5 mg/kg | General | Systemic |
| | | | bw/day | population | |
| Hexanoic acid, 2-ethyl-, zinc salt, | DNEL | Long term Oral | 3.21 mg/ | [Consumers] General | Systemic |
| basic | DINLL | Long term Oral | kg bw/day | population | Oysternic |
| | DNEL | Long term Dermal | 3.21 mg/ | General | Systemic |
| | | 20119 101111 2 01111011 | kg bw/day | population | |
| | DNEL | Long term Dermal | 6.41 mg/ | Workers | Systemic |
| | | | kg bw/day | | |
| | DNEL | Long term | 10.42 mg/ | General | Systemic |
| | | Inhalation | m³ | population | |
| | DNEL | Long term | 20.83 mg/ | Workers | Systemic |
| in heath and the | חאורו | Inhalation | m ³ | Camaral | Cuatamaia |
| n-butyl methacrylate | DNEL | Long term Dermal | 3 mg/kg bw/day | General population | Systemic |
| | DNEL | Long term Dermal | 5 mg/kg | Workers | Systemic |
| | DINLL | Long term Dermai | bw/day | VVOIKCIS | Oysternic |
| | DNEL | Long term | 66.5 mg/m ³ | General | Systemic |
| | | Inhalation | 5 . | population | |
| | DNEL | Long term | 366.4 mg/ | General | Local |
| | | Inhalation | m³ | population | |
| | DNEL | Long term | 409 mg/m ³ | Workers | Local |
| | DATE | Inhalation | 4450 | NA | |
| | DNEL | Long term | 415.9 mg/ | Workers | Systemic |
| | DNEL | Inhalation Short term Dermal | m³ 1 % | General | Local |
| | DINEL | Short term Dermai | 1 70 | population | Local |
| | DNEL | Long term Dermal | 1 % | General | Local |
| | J. 1.L.L | | | population | |
| | DNEL | Short term Dermal | 1 % | Workers | Local |
| | DNEL | Long term Dermal | 1 % | Workers | Local |
| decanedioic acid, 1,10-bis | DNEL | Long term Oral | 0.18 mg/ | General | Systemic |
| (1,2,2,6,6-pentamethyl-4-piperidinyl) | | | kg bw/day | population | |
| ester, mixt. with 1-methyl 10- | | | | | |
| (1,2,2,6,6-pentamethyl-4-piperidinyl) | | | | | |
| decanedioate | DNE | Long term | 0.31 ma/m3 | General | Systemic |
| | DNEL | Inhalation | 0.31 mg/m ³ | population | Systemic |
| | DNEL | Long term Dermal | 0.9 mg/kg | General | Systemic |
| | J. 1.L.L | | bw/day | population | |
| | DNEL | Long term | 1.27 mg/m ³ | Workers | Systemic |
| | | Inhalation | | | |
| | DNEL | Long term Dermal | 1.8 mg/kg | Workers | Systemic |
| | | | bw/day | _ | |
| 2-Hydroxyethyl methacrylate | DNEL | Long term Oral | 0.83 mg/ | General | Systemic |
| | חאבי | Long torm Dame - | kg bw/day | population | Cyatamia |
| | DNEL | Long term Dermal | 0.83 mg/ | General | Systemic |
| | DNEL | Long term Dermal | kg bw/day 1.3 mg/kg | population Workers | Systemic |
| | DIVLL | Long tolli Dellilal | 1.0 mg/kg | TTORKOIS | Systemio |
| į | | ı | ı I | ! | İ |

Date of issue/Date of revision: 27.03.2023Date of previous issue: No previous validationVersion: 19/19

SECTION 8: Exposure controls/personal protection

| | DNEL | Long term Inhalation | bw/day 2.9 mg/m³ | General population | Systemic |
|----------------------|------|-------------------------|---------------------|-----------------------|----------|
| | DNEL | Long term Inhalation | 4.9 mg/m³ | Workers | Systemic |
| Oleic acid, compound | DNEL | Long term Oral | 5 μg/kg bw/ dav | General population | Systemic |
| | DNEL | Long term Dermal | 5 μg/kg bw/ day | | Systemic |
| | DNEL | Long term Dermal | , | Workers | Systemic |
| | DNEL | Long term Inhalation | 17.4 μg/m³ | General population | Systemic |
| | DNEL | Long term Inhalation | 98.4 μg/m³ | Workers | Systemic |

PNECs

| Product/ingredient name | Compartment Detail | Value | Method Detail |
|-------------------------|------------------------|------------------|---------------|
| n-butyl acetate | Fresh water | 0.18 mg/l | - |
| | Marine | 0.018 mg/l | - |
| | Sewage Treatment Plant | 35.6 mg/l | - |
| | Fresh water sediment | 0.981 mg/kg dwt | - |
| | Marine water sediment | 0.0981 mg/kg dwt | - |
| | Soil | 0.0903 mg/kg dwt | - |
| xylene | Fresh water | 0.327 mg/l | - |
| | Marine | 0.327 mg/l | - |
| | Sewage Treatment Plant | 6.58 mg/l | - |
| | Fresh water sediment | 12.46 mg/kg dwt | - |
| | Marine water sediment | 12.46 mg/kg dwt | - |
| | Soil | 2.31 mg/kg dwt | - |
| ethylbenzene | Fresh water | 0.1 mg/l | - |
| | Marine | 0.01 mg/l | - |
| | Sewage Treatment Plant | 9.6 mg/Ĭ | - |
| | Fresh water sediment | 13.7 mg/kg dwt | - |
| | Soil | 2.68 mg/kg dwt | - |
| | Secondary Poisoning | 20 mg/kg | - |

8.2 Exposure controls

Appropriate engineering controls

: Provide adequate ventilation. Where reasonably practicable, this should be achieved by the use of local exhaust ventilation and good general extraction. If these are not sufficient to maintain concentrations of particulates and solvent vapours below the OEL, suitable respiratory protection must be worn.

Individual protection measures

Hygiene measures

: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period.

Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection

: Safety eyewear complying to ISO 16321-1:2022 should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

Skin protection

Hand protection

Date of issue/Date of revision : 27.03.2023 Date of previous issue : No previous validation Version : 1 10/19

SECTION 8: Exposure controls/personal protection

There is no one glove material or combination of materials that will give unlimited resistance to any individual or combination of chemicals.

The breakthrough time must be greater than the end use time of the product.

The instructions and information provided by the glove manufacturer on use, storage, maintenance and replacement must be followed.

Gloves should be replaced regularly and if there is any sign of damage to the glove material.

Always ensure that gloves are free from defects and that they are stored and used correctly.

The performance or effectiveness of the glove may be reduced by physical/chemical damage and poor maintenance.

Barrier creams may help to protect the exposed areas of the skin but should not be applied once exposure has occurred.

Gloves

Wear suitable gloves tested to ISO 374-1:2016.

Not recommended, gloves(breakthrough time) < 1 hour: PVC (> 0.5 mm)

May be used, gloves(breakthrough time) 4 - 8 hours: neoprene (> 0.35 mm), butyl rubber (> 0.4 mm), Viton® (> 0.7 mm)

Recommended, gloves(breakthrough time) > 8 hours: 4H/Silver Shield® (> 0.07 mm), Teflon (> 0.35 mm), nitrile rubber (> 0.4 mm), polyvinyl alcohol (PVA) (> 0.3 mm)

For right choice of glove materials, with focus on chemical resistance and time of penetration, seek advice by the supplier of chemical resistant gloves.

The user must check that the final choice of type of glove selected for handling this product is the most appropriate and takes into account the particular conditions of use, as included in the user's risk assessment.

Body protection

: Personnel should wear antistatic clothing made of natural fibres or of high-temperature-resistant synthetic fibres.

Other skin protection

: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection

: If workers are exposed to concentrations above the exposure limit, they must use a respirator according to EN 140. Use respiratory mask with charcoal and dust filter when spraying this product, according to EN 14387 (as filter combination A2-P2). In confined spaces, use compressed-air or fresh-air respiratory equipment. When use of roller or brush, consider use of charcoalfilter.

: Lowest known value: 126°C (258.8°F) (n-butyl acetate). Weighted average:

Environmental exposure controls

: Do not allow to enter drains or watercourses.

Controls

SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

9.1 Information on basic physical and chemical properties

Appearance

Physical state : Liquid.
Colour : Aluminium
Odour : Characteristic.
Odour threshold : Not applicable.
Melting point/freezing point : Not applicable.

Initial boiling point and

137.64°C (279.8°F)

boiling range 137.64°C (279.

Flammability: Not applicable.

Lower and upper explosion

limit

: 0.8 - 9.8%

Flash point : Closed cup: 30°C

Auto-ignition temperature : Lowest known value: 280 to 470°C (536 to 878°F) (hydrocarbons, C9,

aromatics).

Decomposition temperature: Not available.

Date of issue/Date of revision: 27.03.2023Date of previous issue: No previous validationVersion: 111/19

SECTION 9: Physical and chemical properties

pН : Not applicable.

: Kinematic (40°C): >20.5 mm²/s **Viscosity**

Solubility in water : Not available. Partition coefficient: n-octanol/ : Not available.

water

Highest known value: 1.5 kPa (11.3 mm Hg) (at 20°C) (n-butyl acetate). Vapour pressure

Weighted average: 1.11 kPa (8.33 mm Hg) (at 20°C)

: Highest known value: 1 (n-butyl acetate) Weighted average: 0.88compared with **Evaporation rate**

butyl acetate

Density : 1.156 to 1.398 g/cm³

Highest known value: 4 (Air = 1) (n-butyl acetate). Weighted average: 3.87 Vapour density

(Air = 1)

: Not available. **Explosive properties Oxidising properties** : Not available.

Particle characteristics

Median particle size : Not applicable.

9.2 Other information

hazardous reactions

No additional information.

SECTION 10: Stability and reactivity

10.1 Reactivity : No specific test data related to reactivity available for this product or its ingredients.

10.2 Chemical stability : Stable under recommended storage and handling conditions (see Section 7).

10.3 Possibility of : Under normal conditions of storage and use, hazardous reactions will not occur.

10.4 Conditions to avoid : When exposed to high temperatures may produce hazardous decomposition products.

10.5 Incompatible materials : Keep away from the following materials to prevent strong exothermic reactions:

oxidising agents, strong alkalis, strong acids.

10.6 Hazardous : Decomposition products may include the following materials: carbon monoxide, carbon dioxide, smoke, oxides of nitrogen. decomposition products

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapour concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Symptoms and signs include headache, dizziness, fatique, muscular weakness, drowsiness and, in extreme cases, loss of consciousness.

Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption through the skin.

If splashed in the eyes, the liquid may cause irritation and reversible damage.

Ingestion may cause nausea, diarrhea and vomiting.

This takes into account, where known, delayed and immediate effects and also chronic effects of components from short-term and long-term exposure by oral, inhalation and dermal routes of exposure and eye contact.

Contains n-butyl methacrylate, decanedioic acid, 1,10-bis(1,2,2,6,6-pentamethyl-4-piperidinyl) ester, mixt. with 1-methyl 10-(1,2,2,6,6-pentamethyl-4-piperidinyl) decanedioate, 2-hydroxyethyl methacrylate. May produce an allergic reaction.

Acute toxicity

Date of issue/Date of revision : 27.03.2023 12/19 Date of previous issue Version :1 : No previous validation

SECTION 11: Toxicological information

| Product/ingredient name | Result | Species | Dose | Exposure |
|-----------------------------|------------------------|------------|--------------|----------|
| n-butyl acetate | LC50 Inhalation Vapour | Rat | >21.1 mg/l | 4 hours |
| | LD50 Dermal | Rabbit | >17600 mg/kg | - |
| | LD50 Oral | Rat | 13100 mg/kg | - |
| xylene | LC50 Inhalation Vapour | Rat | 20 mg/l | 4 hours |
| | LD50 Oral | Rat | 4300 mg/kg | - |
| | TDLo Dermal | Rabbit | 4300 mg/kg | - |
| ethylbenzene | LC50 Inhalation Vapour | Rat - Male | 17.8 mg/l | 4 hours |
| | LD50 Dermal | Rabbit | >5000 mg/kg | - |
| | LD50 Oral | Rat | 3500 mg/kg | - |
| n-butyl methacrylate | LD50 Oral | Rat | 16 g/kg | - |
| 2-Hydroxyethyl methacrylate | LD50 Oral | Rat | 5050 mg/kg | - |

Acute toxicity estimates

| Product/ingredient name | Oral (mg/ kg) | Dermal (mg/kg) | Inhalation (gases) (ppm) | Inhalation (vapours) (mg/l) | Inhalation (dusts and mists) (mg/l) |
|-----------------------------|------------------|-------------------|--------------------------------|-----------------------------------|--|
| Hardtop XP Alu Comp A | N/A | 13130.7 | N/A | 181.3 | N/A |
| n-butyl acetate | 13100 | N/A | N/A | N/A | N/A |
| xylene | 4300 | 1100 | N/A | 20 | N/A |
| ethylbenzene | 3500 | N/A | N/A | 17.8 | N/A |
| n-butyl methacrylate | 16000 | N/A | N/A | N/A | N/A |
| 2-Hydroxyethyl methacrylate | 5050 | N/A | N/A | N/A | N/A |

Irritation/Corrosion

| Product/ingredient name | Result | Species | Score | Exposure | Observation |
|---|----------------------|------------------------------------|-------|------------------------|-------------|
| xylene | Eyes - Mild irritant | Rabbit | - | 87 milligrams | - |
| | Skin - Mild irritant | Rat | - | 8 hours 60 microliters | - |
| Hexanoic acid, 2-ethyl-, zinc salt, basic | Eyes - Mild irritant | Mammal - species unspecified | - | - | - |
| n-butyl methacrylate | Eyes - Mild irritant | Mammal - species unspecified | - | - | - |
| | Skin - Mild irritant | Rabbit | - | 500 microliters | - |
| 2-Hydroxyethyl methacrylate | Eyes - Mild irritant | Mammal - species unspecified | - | - | - |
| | Skin - Mild irritant | Mammal - species unspecified | - | - | - |

Sensitisation

| Product/ingredient name | Route of exposure | Species | Result |
|-----------------------------|-------------------|------------------------------|-------------|
| n-butyl methacrylate | skin | Mammal - species unspecified | Sensitising |
| 2-Hydroxyethyl methacrylate | skin | Mammal - species unspecified | Sensitising |

Mutagenicity

No known significant effects or critical hazards.

Carcinogenicity

No known significant effects or critical hazards.

Reproductive toxicity

Developmental effects: No known significant effects or critical hazards.

Date of issue/Date of revision : 27.03.2023 Date of previous issue : No previous validation Version : 1 13/19

SECTION 11: Toxicological information

Fertility effects

: No known significant effects or critical hazards.

Teratogenicity

No known significant effects or critical hazards.

Specific target organ toxicity (single exposure)

| Product/ingredient name | Category | Route of exposure | Target organs |
|-----------------------------|------------|-------------------|------------------------------|
| n-butyl acetate | Category 3 | - | Narcotic effects |
| xylene | Category 3 | - | Respiratory tract irritation |
| hydrocarbons, C9, aromatics | Category 3 | - | Respiratory tract irritation |
| | Category 3 | | Narcotic effects |
| n-butyl methacrylate | Category 3 | - | Respiratory tract irritation |

Specific target organ toxicity (repeated exposure)

| Product/ingredient name | Category | Route of exposure | Target organs |
|--------------------------------------|--------------------------|-------------------|------------------|
| ethylbenzene Oleic acid, compound | Category 2 Category 2 | - | hearing organs - |

Aspiration hazard

| Product/ingredient name | Result |
|---|---|
| xylene ethylbenzene hydrocarbons, C9, aromatics hydrocarbons, C10-C13, n-alkanes, isoalkanes, cyclics, < 2% aromatics | ASPIRATION HAZARD - Category 1 |

11.2 Information on other hazards

11.2.1 Endocrine disrupting properties

Not available.

11.2.2 Other information

Not available.

SECTION 12: Ecological information

12.1 Toxicity

There are no data available on the mixture itself.

Do not allow to enter drains or watercourses.

The mixture has been assessed following the summation method of the CLP Regulation (EC) No 1272/2008 and is classified for eco-toxicological properties accordingly. See Sections 2 and 3 for details.

| Product/ingredient name | Result | Species | Exposure |
|---|-----------------------------------|--------------------------------------|----------|
| xylene | Acute LC50 8500 µg/l Marine water | Crustaceans - Palaemonetes pugio | 48 hours |
| | Acute LC50 13400 μg/l Fresh water | Fish - Pimephales promelas | 96 hours |
| ethylbenzene | Acute EC50 7700 µg/l Marine water | Algae - Skeletonema costatum | 96 hours |
| _ | Acute EC50 2.93 mg/l | Daphnia | 48 hours |
| | Acute LC50 4.2 mg/l | Fish | 96 hours |
| hydrocarbons, C9, aromatics | Acute EC50 <10 mg/l | Daphnia | 48 hours |
| | Acute IC50 <10 mg/l | Algae | 72 hours |
| | Acute LC50 <10 mg/l | Fish | 96 hours |
| Hexanoic acid, 2-ethyl-, zinc salt, basic | Acute LC50 12.8 mg/l | Fish | 96 hours |
| n-butyl methacrylate | Chronic NOEC 2.6 mg/l Fresh water | Daphnia - Daphnia magna - Neonate | 21 days |

Date of issue/Date of revision : 27.03.2023 Date of previous issue : No previous validation Version : 1 14/19

| Hardtop XP Alu Comp A SECTION 12: Ecological information | | | | |
|--|--|-----------------|---------------------|--|
| | | | | |
| | Acute LC50 0.9 mg/l Chronic NOEC 1 mg/l | Fish Daphnia | 96 hours 21 days | |

Conclusion/Summary

: This material is harmful to aquatic life with long lasting effects.

12.2 Persistence and degradability

Conclusion/Summary: Not available.

| Product/ingredient name | Aquatic half-life | Photolysis | Biodegradability |
|-----------------------------|-------------------|------------|------------------|
| xylene | - | - | Readily |
| ethylbenzene | - | | Readily |
| hydrocarbons, C9, aromatics | - | | Not readily |

12.3 Bioaccumulative potential

| Product/ingredient name | LogPow | BCF | Potential |
|-------------------------------|--------|-------------|-----------|
| n-butyl acetate | 2.3 | - | low |
| xylene | 3.12 | 8.1 to 25.9 | low |
| ethylbenzene | 3.6 | - | low |
| hydrocarbons, C9, aromatics | - | 10 to 2500 | high |
| hydrocarbons, C10-C13, n- | - | 10 to 2500 | high |
| alkanes, isoalkanes, cyclics, | | | |
| < 2% aromatics | | | |
| Hexanoic acid, 2-ethyl-, zinc | - | 60960 | high |
| salt, basic | | | |
| n-butyl methacrylate | 2.99 | - | low |
| 2-Hydroxyethyl methacrylate | 0.42 | - | low |

12.4 Mobility in soil

Soil/water partition coefficient (Koc)

: Not available.

Mobility (Noc)

: Not available.

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Endocrine disrupting properties

Not available.

12.7 Other adverse effects

No known significant effects or critical hazards.

Date of issue/Date of revision : 27.03.2023 Date of previous issue : No previous validation Version : 1 15/19

SECTION 13: Disposal considerations

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

13.1 Waste treatment methods

Product

Methods of disposal

: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.

Hazardous waste

: Yes.

Disposal considerations

Do not allow to enter drains or watercourses.

Dispose of according to all federal, state and local applicable regulations.

If this product is mixed with other wastes, the original waste product code may no longer apply and the appropriate code should be assigned.

For further information, contact your local waste authority.

European waste catalogue (EWC)

The European Waste Catalogue classification of this product, when disposed of as waste, is:

| Waste code | Waste designation |
|------------|---|
| 08 01 11* | Waste paint and varnish containing organic solvents or other dangerous substances |

Packaging

Methods of disposal

: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

Disposal considerations

: Using information provided in this safety data sheet, advice should be obtained from the relevant waste authority on the classification of empty containers. Empty containers must be scrapped or reconditioned.

Dispose of containers contaminated by the product in accordance with local or national legal provisions.

| | • . | |
|-------------------|-----------|---|
| Type of packaging | | European waste catalogue (EWC) |
| CEPE Guidelines | 15 01 10* | packaging containing residues of or contaminated by |

Special precautions

: This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapour from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

| ADR/RID | ADN | IMDG | IATA |
|---------|--------|---------------|-----------------------|
| UN1263 | UN1263 | UN1263 | UN1263 |
| Paint | Paint | Paint | Paint |
| 3 | 3 | 3 | 3 |
| | Paint | Paint Paint 3 | Paint Paint Paint 3 3 |

Hardtop XP Alu Comp A **SECTION 14: Transport information** Ш Ш Ш Ш 14.4 Packing group No. No. No. 14.5 Yes. **Environmental**

Additional information

hazards

ADR/RID : Hazard identification number 30

Tunnel code (D/E)

ADR/RID: Viscous substance. Not restricted, ref. chapter 2.2.3.1.5 (applicable to

receptacles < 450 litre capacity).

: The product is only regulated as an environmentally hazardous substance when **ADN**

transported in tank vessels.

Emergency schedules F-E, S-E **IMDG**

IMDG: Viscous substance. Transport in accordance with paragraph 2.3.2.5

(applicable to receptacles < 450 litre capacity).

14.6 Special precautions for

Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in

the event of an accident or spillage.

14.7 Maritime transport in bulk according to IMO

instruments

: Not available.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances,

mixtures and articles

Other EU regulations

VOC : The provisions of Directive 2004/42/EC on VOC apply to this product. Refer to the

product label and/or technical data sheet for further information.

VOC for Ready-for-Use

Mixture

: Not available.

: Not applicable.

Industrial emissions (integrated pollution prevention and control) - : Listed

Air

Industrial emissions (integrated pollution prevention and control) - : Listed

Water

Ozone depleting substances (1005/2009/EU)

Date of issue/Date of revision : 27.03.2023 Date of previous issue Version :1 17/19 : No previous validation

SECTION 15: Regulatory information

Not listed.

Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

Persistent Organic Pollutants

Not listed.

Seveso Directive

This product may add to the calculation for determining whether a site is within the scope of the Seveso Directive on major accident hazards.

National regulations

Industrial use

: The information contained in this safety data sheet does not constitute the user's own assessment of workplace risks, as required by other health and safety legislation. The provisions of the national health and safety at work regulations apply to the use of this product at work.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

15.2 Chemical safety

assessment

: No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

Indicates information that has changed from previously issued version.

Abbreviations and acronyms

: ATE = Acute Toxicity Estimate

CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No.

1272/2008]

DMEL = Derived Minimal Effect Level
DNEL = Derived No Effect Level

EUH statement = CLP-specific Hazard statement

N/A = Not available

PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number

SGG = Segregation Group

vPvB = Very Persistent and Very Bioaccumulative

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

| Classification | Justification |
|----------------|---|
| 1 - 7 | On basis of test data Calculation method Calculation method |

Full text of abbreviated H statements

Date of issue/Date of revision: 27.03.2023Date of previous issue: No previous validationVersion: 118/19

SECTION 16: Other information

| H225 | Highly flammable liquid and vapour. |
|--------|--|
| H226 | Flammable liquid and vapour. |
| H304 | May be fatal if swallowed and enters airways. |
| H312 | Harmful in contact with skin. |
| H315 | Causes skin irritation. |
| H317 | May cause an allergic skin reaction. |
| H319 | Causes serious eye irritation. |
| H332 | Harmful if inhaled. |
| H335 | May cause respiratory irritation. |
| H336 | May cause drowsiness or dizziness. |
| H361d | Suspected of damaging the unborn child. |
| H361f | Suspected of damaging fertility. |
| H373 | May cause damage to organs through prolonged or repeated exposure. |
| H400 | Very toxic to aquatic life. |
| H410 | Very toxic to aquatic life with long lasting effects. |
| H411 | Toxic to aquatic life with long lasting effects. |
| H412 | Harmful to aquatic life with long lasting effects. |
| EUH066 | Repeated exposure may cause skin dryness or cracking. |

Full text of classifications [CLP/GHS]

| Acute Tox. 4 | ACUTE TOXICITY - Category 4 |
|-------------------|---|
| Aquatic Acute 1 | SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1 |
| Aquatic Chronic 1 | LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1 |
| Aquatic Chronic 2 | LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 2 |
| Aquatic Chronic 3 | LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3 |
| Asp. Tox. 1 | ASPIRATION HAZARD - Category 1 |
| Eye Irrit. 2 | SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2 |
| Flam. Liq. 2 | FLAMMABLE LIQUIDS - Category 2 |
| Flam. Liq. 3 | FLAMMABLE LIQUIDS - Category 3 |
| Repr. 2 | REPRODUCTIVE TOXICITY - Category 2 |
| Skin Irrit. 2 | SKIN CORROSION/IRRITATION - Category 2 |
| Skin Sens. 1 | SKIN SENSITISATION - Category 1 |
| Skin Sens. 1A | SKIN SENSITISATION - Category 1A |
| STOT RE 2 | SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 2 |
| STOT SE 3 | SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE - Category 3 |

Date of printing : 27.03.2023 Date of issue/ Date of : 27.03.2023

revision

Date of previous issue : No previous validation

Version : 1

Notice to reader

The information in this document is given to the best of Jotun's knowledge, based on laboratory testing and practical experience. Jotun's products are considered as semi-finished goods and as such, products are often used under conditions beyond Jotun's control. Jotun cannot guarantee anything but the quality of the product itself. Minor product variations may be implemented in order to comply with local requirements. Jotun reserves the right to change the given data without further notice.

Date of issue/Date of revision : 27.03.2023 Date of previous issue : No previous validation Version : 1 19/19